Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Orbis Medicines has raised $93.5M in total funding. The most recent round was Corporate Round. The last funding was announced in September 2026.
Orbis Medicines's investors include Eli Lilly, New Enterprise Associates, Forbion Capital Partners, Cormorant Asset Management, Novo Holdings.
Orbis Medicines is headquartered in Frederiksberg, Denmark.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Orbis Medicines is at the Corporate Round stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orbis Medicines — Funding & Investors." VCBacked, September 17, 2026, https://www.vcbacked.co/company/orbis-medicines. Accessed October 17, 2026.
VCBacked. (2026). Orbis Medicines — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/orbis-medicines
{{cite web |title=Orbis Medicines — Funding & Investors |url=https://www.vcbacked.co/company/orbis-medicines |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated